isple used to say pharma dead, the pipeline is empty, big problem.ng new drugs and hepatitis and cancer and there's a lot of stuff coming down the pipeline. people have more faith in the industry. ofis there a broader appeal different kinds of investors looking at the health care etf? >> i talked to a lot of specialists on the buy side and the sell side. , people more and more going sector to sector, looking at health care. one analyst says he's done more presentations for generalist investors then he has in several months. allow has the eba affected of us? there was some concern would be bad for the health-care industry and then it shifted to good. is that having any effect? >> look at how the sector performed in the years leading up to passage and right after, what you saw is in 2010 from april, right after the law was signed through december 31, about $944 million flat out of exchange traded funds. as money wasng out pouring in to etf's and that has turnaround. you saw the concern about how is the law going to work and who is going to get hurt by

i wonder if the big pharmas don't come in and say, hey, i can do that? always a foundation to valuation in the biotech space. david: that could rise both boats, both boats of big pharma that is get involved and smaller biogen companies? >> absolutely. we're seeing big pharma buy innovation to perpetuate its growth. david: okay. small caps, because we like sometimes these small caps. a little more risk if you're interested in investing in small caps and people can manipulate. how do you pronounce it novo vacs. >> novavax. david: why do you like it. >> it is a next generation vaccine company. today you get your flu vaccine every year. it is very cumbersome product. they have to inject eggs to grow these vaccines. what novavax is doing modern biotech techniques to grow these much faster, much cheaper. what is really exciting, they have a contract with the government to develop seasonal and in case of the worst, a pan them dick flu vaccine but they have also got a respiratory vaccine or rsv vaccine. this is actually number one cause of hospitalization in bab

we know that doctors and big pharma have a close relationship. of course, they meet all the time.t this or what concerns you? >> well it's happened for decades, pharmaceutical companies have worked with doctors both to treat conditions and to help promote those medications. and the promotion part has gotten a lot of attention because drug companies have paid billions of dollars to settle lawsuits and giving kickbacks to doctors. so this has gotten a lot of attention over the years because of that. >> so you may be suggesting that they're prescribing drugs not because their patients may need them but because they're being paid by pharma to prescribe them. >> some doctors make tens of thousands or hundreds of thousands of dollars a year beyond their normal practice just for work with street. >> now, what i was going to ask you, how much money are we talking about here. and you just answered that. and why should we care if the doctor is making extra money, why should we be concerned? >> when you go to your doctor trust that the doctor is giving the best medication four but there's a

that's defeated bio and sending people to pharma.amer. >>> when money talks it comes to cramer first. >> why are you so bullish? >> we see the huge recovery potential in the united states. >> we are in control of the destiny in this country. we need to get after it. >> in our industry you're riding that innovation curve or you're no. >> my message is don't bet against us. >> watch "mad money" and be the first to know. first to know. ♪ humans -- we are beautifully imperfect creatures, living in an imperfect world. that's why liberty mutual insurance has your back, offering exclusive products like optional better car replacement, where, if your car is totaled, we give you the money to buy one a model year newer. call... and ask an insurance expert about all our benefits today, like our 24/7 support and service, because at liberty mutual insurance, we believe our customers do their best out there in the world, so we do everything we can to be there for them when they need us. plus, you could save hundreds when you switch -- up to $423.

that's defeated bio and sending people to pharma.h cramer. >>> when money talks it comes to cramer first. >> why are you so bullish? >> we see the huge recovery potential in the united states. >> we are in control of the destiny in this country. we need to get after it. >> in our industry you're riding that innovation curve or you're no. >> my message is don't bet against us. we're going to be the winner in this industry. >> watch "mad money" and be the first to know. >>> tonight larry kudlow will bid farewell to "the kudlow report." the civil place to discuss economics and politics. his show and "mad money" too came in the wake of our decision to create two hours of television from one. kudlow and cramer. our forerunner. the show's hallmark was fairness to both sides of the aisle. and to each other as befitting the coin flip from a real ncaa ref to see whose name went first in the credits. i obviously lost. i got a chance to say good-bye to the gentleman and emotions ran high. we had to stay focused on the substance though. as larry

farm pharma sycilx. it is stock picking. if you picked these ones, you did well. >> josh, look, five years ago i walk around this floor, i don't know how many people through of 3d. >> or tesla. >> now people are talking about it because of the rise that dom mentioned. >> wholesale industries were basically invented since the market bottom that didn't exist. tesla is a great example. the social media stocks were concepts at that point and 3d systems is another great example. there was no such thing as 3d printing and now it's commercially viable and every company in the world is trying to make use of the property. >> las vegas sands. >> i pounded the table for this one in '09, judge. i pounded it for a number of financials. even the triple bull financial right here on cnbc. i said, folks, these things have at least 100% upside in the short term. the fas, scott, went from $147 to $94. look at stocks like bank america, citi, even with these splits you dial those back in from those lows in march of 2009, absolute crazy performan

this time we're on the event of the northern pharma payroll report. we rally ahead of it. the short sellers lock in profits, and we're scared that the markets are so oversold that it's due for a hefty rally after decline. day five, that's friday. labor and ukraine take center stage again as we fret about a battle with russia over the weekend. that's the day we see stabilization in the high growth stocks that become our leaders. either because the economy is weak and managers want growth or because the economy is okay. the employment numbers are now behind us. the stability sets in. that's pretty much the may fly-like life cycle of all these types of sell-offs. those who buy on day one tend not to do well at all, which emboldened sellers on day two. at the end of tomorrow you need to break out the shopping list, but you might have to absorb some buffet-like pain. heaven forbid we get a selloff on ukraine fears, and then just have to dust off what worked well starting three weeks ago when the market got crushed off of fears about other emerging markets. oh, the usual caveat,

but she tells the round on an anti corruption ticket the session as sun pharma sms condition of man but managing a distant second place with any fifteen cents strong earthquake has struck the frills and today triggering a brief evacuation i think it's six point seven quake was centered sixty k to make this up because it takes the cake. no injuries were recorded around one hundred thousand people were evacuated as most of them heading off to nearby hills there's been no clashes in venice when no one months on from the fast outbreak in the capital bought a seat up to the sun and several thousand dependents of the country says his government were prevented by police from marching on a minute. the ad based in caracas in the last four weeks twenty eight people died in the country's worst unrest in decades. loom zz you. it was your son the double victory of the old landscape world cup thanks to muscle hash and the pentagon who had to see some highlights. welcome to gravity. it was. the season with the challenge of becoming the first monday noted that he is with the welsh cup titles for use in

but she tells the round on an anti corruption ticket the session as sun pharma sms condition of man look like managing a distant second place with any fifteen cents. the stone as they test all the frills and today triggering a brief evacuation i think it's six point seven quake was centered sixty k to make this up because it takes the cake. no injuries were recorded around one hundred thousand people were evacuated as most of them heading off to nearby hills i have been no clashes in venice when no one months on from the fast outbreak in the capital finance erupted on sunday when several thousand dependents of the country says his government were prevented by police for munching on a minute. the ad based in caracas in the last four weeks twenty eight people died in the country's worst unrest in decades. nm. i started twelve years austria celebrate it a double victory of the old landscape world cup thanks to muscle hash and the pentagon who had to see some hi welcome to gravity it was. the season with the challenge of becoming the first monday noted that he is with the welsh cup title for

and biotech company "recro pharma" is also slated to debut stock, with shares pricing in range of $10-$12 dollars under ticker r-e-p-h. advertisers are smiling following the big night at the oscar's. pepsico, mcdonalds and american express and cadillac all made an appearence during the big show. the show continues to gain a massive following on traditional and social media. this year, oscar ad prices shot up to 1.8 million dollars for 30 seconds of air time. southern california is finally receving some much needed rain. but the unusually dry winter still has many crop growers bracing for the worst. ky sisson takes us to riverside county, california where wineries are encountering both doom... and boom! every morning greg pennyroyal checks the forecast to see if rain is coming his way. without water we would be out of business. normally this time of year, i would have anywhere from 12-18 inches. keeping his vineyard alive is the challenge he faces as the vineyard manager at wilson creek winery in temecula, california. to make up for the lack of rain, pennyroyal has had to turn on the i

a lot of movement in biotech and pharma. specific test results.or edwards life sciences, studies released shows perhaps we could see an increase of the man-made heart balls that can be inserted without cracking the chest open. study beinghe presented at the american cardiology conference underway right now. medtronic rising on similar studies. biogenic rising as well as they get approval for hemophilia b treatment, which will allow patients to get treatments less frequently than existing treatments. those are part of the assisting upside and treatment -- and pharma today. janet yellen vacated the market today by suggesting rates are not going up, at least in no point in the near future. yellen indicated the economy will need the fed support for some time. the federal reserve takes the gold very seriously. one reason i believe it is appropriate to continue to provide substantial help to the labor market without adding to the risks of inflation was because of the evidence i see that there remains considerable slack in the economy and labor market. >

shares of zojenix the maker of that controversial painkiller zohydro plunged on news that purdue pharma is moving ahead with a rival. experts say the drug is too powerful and potentially addictive. the stock tumbled about 23% to $3.51. and krispy kreme results also out after the market close today. the doughnutmaker said profit more than tripled on improved sales. it also boosted its earnings forecast and increased its share buy back program. shares rose right after the report. the stock ended the regular session up almost 2.5% to $19.88. and a company that might be gearing up to go public is a little-known data security firm with a growing roster of big-name clients. it's already getting a lot of attention from investors. josh lipton has more. >> reporter: there's always buzz in silicon valley about what company could be the next hot ipo. a name that's often mentioned, palantere. the case is easy to make. palantere's specialty is crunching massive amounts of data so that organizations can make sense of it. its clients include the department of defense, the los angeles police department

you sell biotech and pharma stocks go up. half, medical distribution, just benefit from volume. more people getting signed up and going to the system, so hospitals and distributors -- i think the stoxx work because of the growth rate in the valuation they offer. >> and open parker is the ipo market -- adam parker is the ipo market a good sign of things to come whether it is keene digital or twitter ipo? economyrically, the improved. you saw more m&a. i think corporate, the managements have been a little more sober. an all-timerket as high. i think part of it is because we know we're running a deficit physically and part we know we have a lot of accommodation monetarily. i think that is a good thing that could make the cycle last longer than people realize. maybe he could go as long as 2020. >> adam parker, thank you. the red sox! we look at the red sox the mayor white will to do with us. i want to talk about his important new book. last day of the quarter. i haven't made a dime in my foreign-exchange. ruble is putin-friendly.

pharma agricultural business is 10.8 cents.actually is netting out factors such as energy, transportation. these go into their own the sectors. there is a piece of the fiber of them out for energy prices and transportation. we are really just talking about commodity rices and farm labor. that is around 11%. simple back of the envelope copulation, if commodity prices , we would expect to see food prices go up around 10%. that is substantial. it is not catastrophic even given the stork increase in commodity prices across the country. berry is waiting in new jersey. is when wequestion have a drought in camden, does this have anything to do with pollution or because the ground is a poor farming area? what about the quality of the food? a severe weather event retaildrought can impact food prices and that depends on what the production is in the area. in new jersey, if there is a drought or a problem locally, you're more likely to see an impact in local or regional food prices. a lot of retailers across the united states and gotten v

that program is a boondoggle, i give away to bake pharma. he should not have voted for it. that is that. frankly, i cannot recall an occasion where i got more slack. as you know, it has turned out to be an extraordinary success story. they have come in 45%, 45 percent below projected cost. and there really is not anybody in the congress here now talks about repeal or derailing it. that is because an enormous number of seniors and families have peace of mind and security as a result of making the program work. i bring this up only by way of saying that a lot of the stories a day of the ac a first few months show a remarkable resemblance to the stories about part de in its few months. western civilization is going to hand. the bureaucracy is torturing us. back-and-forth the debate went. what i will try to do on the finance committee is bring the same bipartisan approach that i did in terms of working when a republican president got his major health initiative through and bring that same approach that i used the party to try to work with colleagues in a bipartisan way on the d

look at some of the big pharmas. you have through huge categories in the market that can continue to own. authors areas that i think actually push us towards the 1900 level. to stef's point, you look at basically the data recently it hasn't been that bad here in the u.s. but you always got to keep in mind there's some slowing, some cooling in china right now and john was dead right when he was talking about crimea. we knew what was going to happen, it happened. >> it's worth revisiting what larry altman said on this show on friday. a professional day trader for the first time in a long time started to sniff out some things that seemed a little bit cautious to him, talking about going back to 1500 or so on the s&p. not the 18 in change where we sit today. >> the market is betting against that still. you know we've had some selloffs. we had a two way take. the market is still betting on growth. the way you know that we're almost through the first quarter of this year. let's look what's been work. worst performing secto

that program is a giveaway to big pharma, it george w. bush should not have voted for it. i cannot recall an occasion where i got more flak than when i voted for this. as you know, it has turned out to be an extraordinary success story. the last figures indicated it has come in 45% below projected cost. there really is not anybody in the congress who now talks about appeal or derailing it or something of that nature. an enormous number of seniors have peace of mind and security as a result of making that work. ofring this up only by way saying that a lot of the stories 's few monthshe aca show a remarkable resemblance to the stories about part d in its few months. western civilization is going to end. the bureaucracy is torturing us. ist i'm going to try to do bring the same bipartisan approach as i did in terms of working with a republican president got his major health initiative through. i'm going to bring that same approach should try to work with colleagues in a bipartisan way in the aca. let me use that as a kind of opening. softball questions are especially welcome.

they are roughly speaking 18% of the s&p 500, pharma is a much larger part of the stock market.e ibb against the spy. it's left it in the dust. with respect to the health care sector in particular, it's just 18% of one of ten sectors in the s&p 500. this is not, to dom's point, some broader market sell-off. pharma is more important to the market overall, to health care specifically, that's merck, johnson & johnson. this is not some everybody watch out the whole market is crashing moment. >> kayla, about the same size in this market are the financials. if you want to talk about perhaps a positive story to offset some of the weakness we're seeing here, could you point to the activity we saw last week. >> right. and certainly the financials were on a tear last week. they held up pretty well today, and i think the issue with today's market was that you had a lot of these momentum stocks pulling back and when you see some of these outsized moves in either direction, people generally get a little fearful and they think the entire market is selling off. a lot of defensive names, consum

if you looked at fund flows into health care and biotech and pharma. you're seeing consolidation.an't go up forever. the fundamentals rerain good. >> i would push back and say. i love mel, obviously. but is the question flawed? is there a bubble in the biotech? i don't think there is. i think most of the stocks are reasonable. cellgene has an incredible balance sheet. i don't see a bubble. the stocks have sold off. but i don't think there's a bubble, necessarily. >> that's a good point. our position remains you want to stick to the bigger names and the names with good fundamentals. and lower mid caps, you look. there's been a lot of interest in ipos. a lot of companies are trading at above $1 billion in market cap. without validation of the technology. small mid cap is a little stretched. large cap is okay. they're trading at 20-times and growing 20%, 30%. small cap looks a little stretched to me. >> it's karen. so many of the stories are very particular, unique stories of the different drugs. but they tend to trade all together. definitely there's a correlation here. how much doe

stocks like streaming music provider pandora, 3d systems, pharma six lix and all three stocks firmly in bear market territory now. interesting is three very different stocks, very different industries but losing steam almost in tandem. you can see the line. also on the list, names we like to talk about a lot, netflix, amazon, priceline. a big upswing, now actually all in correction mode. all of these names down at least 10% or more from its recent 52-week high. talk about the buy iotechs. a big winner losing steam now. ishares index ibb down about 15% from its highs. here's the thing. it's not just about high-flying momentum names, nope look at this home builder. even retailer american eagle outfits. those two stocks perhaps stock-specific stories nonetheless in bear market territory. the big question is, why? what are we seeing now? saying, look, all of this speculation is for sale. seeing rotation from growth to value. yes, seeing casualties. here's the question, though -- is this just the tip of the iceberg? a senate for the rest of the market? or one example of a group very overv

this year, only 13 are trading below their offer price and seven of those are from the biotech and pharma space. lastly it's the huge opening returns of tech ipos have made some investors nervous. while seeing a 22% first-day drop. tech ipos have been averages a pop. experts say be cautious. names that have moved up so fast have farther room to fall. >> well, that is always the case with those ipos. sexy at the start, but they can catch you. seema, thank you. all right, sue, down to you. >> let's go to chicago, because rick santelli is back in the aftermarket to talk about that two-year note auction and how things are going right now. ricky? >> yeah, two-year note auction wasn't bad. but of course it's going to be the fives that are a bigger task form. looking at fives, yes the yields are up a bit. but if you look at the other end of the curve, we see the real movement. and that is the reverse of flattening. it doesn't take away a lot of what occurred after the statement wednesday. if we look at what's going on with regard to foreign exchange, no chart is better than the dollar/yen. we co

the big pharma names are going to be consistent. >> you know, i get the whole biotech thing but as a retail investor i would be cautious. i would stick to amgen, merck, and pfizer. >> coming up, walt disney making a major digital deal to draw more teens into the entertainment empire but what will it mean for the bottom line? >>> as tiffany lost its luster? a trader says it's a diamond in the rough. very classy is on deck. and we'll be right back. >>> tim. four trades and four stocks. first up is disney buyer maker studios for $500 million. it's the largest disney distributors. pete? >> depending on performance this would be a $950 million deal. disney continue to grab content. i think they're getting this cheap right now. great opportunity. 5.5 billion monthly hits they're getting on youtube. >> bank of america adding csx. hitting a all-time high today. >> i think it can still work. i picked it for my final trade today because i think the numbers are low enough expectations are quite reasonable at this point. coal inventories are bottoming. i like it for the u.s. recovery. >> the mak

we're looking pharma, biotechnology and particularly because of gilead sciences. news of hepatitis-c pricing for drugs. jpmorgan says the bubble we've seen or some people calling it a bubble is not a bubble at all for the biotechs that really run up last couple years and actually most recently and a little bit of a breather here but we've seen this group pulling back quite dramatically in the last few sessions. so much so that its noticeable and dates back to august of 2011. so we are watching biotechs very carefully and how they are in turn affecting tech-heavy nasdaq. there are many things that go into the nasdaq, biotech certainly one of them. back to you. melissa: nicole, thank you so much. we know it is were wrong to kick a company when they're down but sometimes you can't help it. so this week we're calling out worst of the worst. from lackluster stock performances to terrible product the and greedy executives. scott martin of united advisors first up with the picks a fox news contributor. you have aol on your list. >> that is a pretty easy one, melissa. ceo

like it but it's a similar situation to celgene, people do not want to own these big cap biotech pharmasht now, they're out of sync with the financial and tech rally. i think you hold on to it though. phil in maine. >> caller: hey, jim, jim from the snowy state of maine. what do you think about bluebird bio? >> that comes under a different group of biotech. that is the speculative portion. and stocks are going still higher. it's the same problem with sales force and cloud. the speculative part of cloud is going higher. the regular aren't. the speculative part of biotech's going higher, the regular aren't. i want to be careful that can't last forever, i say take profits. let's go to brad in new york. >> caller: hey, jim how's everything? >> how are you? >> caller: good, good. a question with regards to vm ware. >> it's interesting, vm ware, the virtual software, this is it. this is the right one. emc owns a piece of it. emc's also going out. they had a great quarter, vm ware. let's go did alan in louisiana, please. >> caller: boo-yah from the buying easy. >> oh, man, just down there loved

gives you a dividend, much like a big pharma. >> amgen. anybody else? >> i like xbi and ibb.on't like to play particular companies. you wake up with a failed trial. it's the easy way out. but this last run down 16% from the peak. that has been painful. >> it has been very, very painful for a number of those stocks. >>> time for pops and drops. the big movers of the day. let's talk about a drop. gamestop, about 4%, pete. >> and the issue is when you look forward, you look at the guidance and the guidance is not where you wanted it to be. people will be very painful on your stock. they will sell it off. huge day today. maybe a bit of a washout day. double normal volume today. i don't want to buy it yet. but i will look at it now. >> a pop from symantec. >> some activists could get in the name. that puts a floor in the stock. it continues to go higher from here. >> and a pop from cliffs natural. >> speaking of activists, there's activists in this. but it got taken out of the s&p 500 last night, put into the 400. opened lower. ripped higher. i like this space. i'm in this name. i

same thing goes for celgene, regeneron, the four horse men of the pharma. they are not stopped by a second crimea war, neither are the combatants that have created the incredible drugs to try to stop them. then there's the oil and gas revolution that we've focused on for ages. could this be damaged by the incursion into ukraine? hardly. benefit from tensions between russia and western europe. they benefit. consider the company we have on tonight. wow, did you see it today? continental resources. the biggest landowner in the bakken shale in north dakota. here's a company that directly benefits from turmoil that could restrict energy exports from russia, driving up the price of crude worldwide. it know it seems a little illogical given that continental's crude goes to gasoline in this country. remember gasoline in this country is priced off the inflated oil price set in europe, not by the domestic price here. and that means bakken oil is even more valuable to east coast refineries than ever because of what was happening with ukrainian/russian tensions. contin

so yeah, sell noncommercial boy oh tech, mature biotech, like pharma, very cheap. where it's the amgens or gileads. they're cheap. i don't like the commodity-based energy producers because i believe alternative energy is making inroads. and let's face it, we're self sufficient in energy. you've got to be selective in each sector. it's not as easy as sell this sector, buy that sector. >> to steven's point. better energy does in general hydro carbon energy, the better stocks like solar city are going to do because of the alternative space and people will look for another way, especially with the tax breaks they get for it, so that's why i wouldn't want to get in front of that truck, judge, as far as shorting any of those names on the solar city side. >> our next guest says the growth of u.s. oil production is creating in his words a bonanza for the energy industry if you pick stocks carefully. joining us is john dawd, portfolio manager with fidelity. great to have you back. >> great to be here. thank you very much. >> you heard the conversation and obviously you're p

are concerned about this european launch particularly because you are not partnering with a large pharmars to be low margin with little or no impact until the automated process is vol dated. with the possibility of losing money on every sale of provenge, we see the expansion into europe as madness. why would you go it alone when the reaction is so sharp? >> there's a couple of things important to keep in mind. first of all, we have a contract manufacturing organization in europe. in the states, we build our own manufacturing facilities, took a lot of capital. we went with a contract manufacturing organization. second, there's market demand in europe for the product. we heard that from key opinion leaders. it's important to recognize that the european regulators had more data when they evaluated the provenge dla. when they looked at that, in our label is more data about patients who could benefit. a stronger label than we have in the u.s. based upon that, we've taken that to health technology assessment committees in europe. and what they've done is looked at it. in fact, we believe we ha

pharma as well as in varenis. the one thing they're talking about, scott, 3.illion market cap right now. 13 million in revenue and no profits. guys, back to you. >> bertha coombs will have more about that topic, bob. rick, yesterday we were all over this swift drop in yields. now you have some people in articles and otherwise raising questions that we shouldn't be worried about a stock market bubble that it's the bond market that we need to worry about. corporates and emerging market bonds that are the tale. what is your reaction? >> i absolutely completely 100% agree. keep in mind it's like saying that worry about the tail side of the coin but, you know, ignore the head side. they're both very related. it's the credit issues, of course, that can make the likes of the amazons or teslas do what they do and propel their stocks to where they are. in the article you're referencing, nothing he makes is more apparent than the following, if i recall, the numbers were inflows into global bond funds were about 1.2 trillion in change versus equity side which is about 13

big pharma, it's been a broad-based rally. if that can continue out of the financials which i still think there many names there plenty of upside to come, 1900 without any problem. i realize that's only 20 points. from there i think then possibly we start to see some pullbacks because there are areas that i think are extended. >> ben willis on the floor of the new york stock exchange. good number today relative to expectati expectations. why not a better market reaction? >> a story, again, ukraine is shaking the market. a story about gazprom pulling the plug on the ukraine and gas flows took the wind out of the sail. but i think this bull definitely has room to run. i think the legs are a little tired and they need to take a break somewhere. i just don't know when it's going to come. >> you saying it's aging not raging, this bull market? >> it needs to take a break. it's ageing a little bit here. >> anthony, how do you see things? >> i think it's raging. and i know that's probably against the consensus right now and the fact t

doctors about whether adhd actually exists or not but there's no argument that it is big money for big pharmay shows that adhd diagnosis has been made in 15% of high school children and if you look at the number of children who are on medication for it now, we are now at the 3.5 million mark. that's up from just 600,000 in 1990. when you look at sales of stimulant drugs used to treat these children, now, $9 billion, more than five times than just a decade ago. when you talk about players in this space, you talk about scheier pharmaceuticals, the company's number one drug by sales has seen sales nearly double over the past five years. even adderall which raked in nearly $200 million. you talk about novartis with its ritalin drug. another player in the sector which brought in $600 million in sales last year alone. both companies have come under fire for overmarketing the drugs. in fact, recently, shire reached an agreement in principle to pay nearly $60 million in fees to resolve allegations of improper sales and advertising. here's the thing. when you look at these numbers, there is no doubt t

lobbying fromis big pharma, which loses profits because of e-cigarettes.tred of smoking. but when you look at the science of it and helping people, hang on a second. we have got people dying. if this is a way to help that, we should really -- inside the bear have a regulatory function. originally, people in your position told us they welcomed regulation. >> and we do, not knee-jerk reactions to theories. the fda will come down with regulations shortly. we have to make sure it is manufactured right and protecting the consumer. >> thank you so much for joining us today. jason healy, president of blue e-cigarettes. breaking news. you know the fund -- bill ackman's -- they will be conducting a webcast on business practices in china. i have a feeling it will not be a positive presentation. you know bill ackman. the biggest short out there. ♪ quakes that is going to do it. -- >> that is going to do it. tomorrow, simmons is going to rock the house. a new book. thought dan love was the only guy who cared about transcendental meditation. guess again. this hip-hop k

diminishing the china pharma us -- ginormous export economy.lerms of gainers of individual companies, solar city jumped seven percent yesterday. it will be offering solar power in about 60 best buy stores, and customers will get a gift card if they sign up for solar servers through best buy for a certain time. herbalife down seven point four percent. the biggest loss since late january. u.s. federal trade commission is doing a probe into its practices. bill ackman thinking finally something is being done. >> finally. yet he has been long fannie and freddie mac which got crushed yesterday. on because we have all been mystified by what happens with the missing malaysian airline jet. >> so bizarre. >> you have to wonder what happens next. industry a report said grew 10% last year. air disasters discourage people from booking their next big trip? does the unrest in places like ukraine discourage travel as well? we are joined by world travel and tourism council president and ceo. david, welcome. >> good morning. >> as an industry insider, you work f

we have ones where we are taking not a huge scientific risk, so -- you have been inside big pharma only since 2008. you were a consultant at kinsey. if i kinsey consultant was ant right now,e what would they say you are doing right or wrong? >> hopefully they will look at results and see that we are doing a good job in terms of organic growth. awfully they say that when we buy companies, we are not overpaying for them, we are doing it in a way that offers a great return to our shareholders , and hopefully they would say that we have the aggressive ambitions, and that is usually a good thing. >> michael, thank you so much for joining us. i could use that treatment could i'm pretty damn tired today. >> we could all use it. >coming up, a rough start for general motors ceo mary barra. she had barely moved into her new office before the new recall scandal broke out. criminalith toyota's penalty, a lot of people are wondering what is next. >> also, the ipo frenzy. why are so many copies going public this year? ons is "market makers" bloomberg television and streaming on your tablet. ♪ >> welc

novartis is a swiss pharma company. drug, take their test big-name, you live longer. that drug, you live longer. they are coming off trial, going to ask for early marketing for that drug. that is about replenishing the overall revenue flows within novartis. doctorsblockbuster rolling out. euro/dollar, 1.3752. traders preparing themselves for movement? if not, thursday. the consensus is, no movement but preparing themselves for something further out. action? that would be a whole new paradigm for the ecb. >> thank you so much, manus cranny with your market check. joining us for more on the markets, chief investment officer at axis investment management. great to have you on the program. give me a sense of how much you are focused on the ecb. this is the big one. we are expecting them to maybe deal with it this week. >> there has been this long running hope that there might be some stealth qe or action. i would be surprised if they did anything. as far as europe is concerned, the data is a little bit mixed. i think mixed will do. as long as we have that situation in pla

pharma and s&p overall, those valuations have actually increased.bout what russ was saying that investors now really looking for valuation and focusing on those fundamentals saying bye-bye to that froth thiness and big pulls that have pushed the value forward. >> all right. sheel la, little uptown at the nasdaq. coming up next on "squawk on the street," the cutting edge in retail innovation is opening up a shop on the upper east side, since when? the founders of warby parker are with us next on why the e-commerce site is expanding its brick and mortar footprint. ♪ [ male announcer ] how could switchgrass in argentina, change engineering in dubai, aluminum production in south africa, and the aerospace industry in the u.s.? at t. rowe price, we understand the connections of a complex, global economy. it's just one reason over 75% of our mutual funds beat their 10-year lipper average. t. rowe price. invest with confidence. request a prospectus or summary prospectus with investment information, risks, fees and expenses to read and consider carefully bef

arthur modine invented the pharma radiative for trucks. here is the problem.ope helped the mouth, they have been slow to expand and the rest of the world and don't pay dividends. others said guidance for this year -- this is going to be a sideways stock. someone wants to hold longer-term fine but asia is going to be great and south america will be great but they just ramping up. stuart: this is not one of your money making stocks. this is a request from a viewer to cover it and say what you think and you said it. you have a stock to make money with. stuart: it is a semiconductor play but if they make these connected is is all about the internet becoming faster and more stuff traveling on it. they are in all the sweet spot, cloud, web centers, high-performance computing, right now 2.0 satellites travel on the internet. next year it will be 8. you know what that is? one is that a bite, think of one fall by 210s, that is how much more data, tablets, smart phones, video, all of this has to be facilitated, we wanted to be fast. i think this will be a gigantic winne

>> guest: in 96 that was when pharma released the brand-new oxycontin which was a time release opiate. that heretofore hadn't been described for anything other than end-of-life situations so now this new time release thing from what i understand was touted as something that positions could prescribed for moderate or chronic pain situations. they were very ill-advised to do that. it was totally a marketing campaign. during that time a lot of things did get out. i don't think that explains why there is such a glut in the market as there seems to be. more importantly i think the initial question or comment that yes that is where kids mostly get their pills. if you don't know what's in your own medicine cabinet you might want to check it out. part of what a lot of the cities and towns are doing now in terms of forming coalitions to address the problem is making sure that there is a drop box 24/7 at the police station no questions asked. you have old pills hang around or something that had been prescribed years ago. it may be your kids friends. you could have people coming in the house. i

and stock sale value at $600 billion in the corporate merger the combined the company taking for pharmahe laws of ireland. >> number eight, orbitz worldwide, downgraded from buy to neutral, slower grooves -- slower growth coming from selling at a premium. >> number seven, oracle, posting fourth-quarter results as the company faces salesforce.com, helping their rivals sell internet-based programs. they have collected sales growth around five percent and 10 quarters. home, swamping the gain, beating as well is surging. they said that new home orders rose six percent around a higher community count, shares gaining on the news, not so much bad weather. >> number five, the game maker delaying titan fall for xbox 360. released earlier this month for the xbox one helped to boost sales of its newest console. .> number four is not a stock talking about treasury, keeping our eyes on government torowing, right? make sure watch our special coverage of the event today live, when janet yellen host stir first news conference in pairs. -- hosts her first news conference. suspending commercial meetings,

great phonics and services for its consumers and doctors as well as great marketing solutions for pharmanies, insurance companies, everything that will happen over the next couple of years. consumerst helping and doctors and doctors in helping constituents reach each other on the internet. we are excited about this opportunity to invest back in the business. >> tell us how obamacare has impacted your business? obamacare islot of about putting the consumer at the center of health care, empowering the consumer to make choices for themselves and their family and so much of what every day health does is use internet and great brands help consumers make better decisions and manage their health. we are very excited about all the changes going on in health care the consumer gets the rust to the center and the internet is obviously an incredibly useful tool. >> we are talking the internet on a mobile platform, too, with the majority of people turning to mobile devices to consume a lot of content. what are you doing on the mobile front? >> absolutely. mobile is more important than ever. 16 millio

large pharma is flush with cash and pipelines have lost a lot to generics.as lost a lot to generic competition. a lot of the last run we have had was stimulated by a gilead acquisition with small biotech company. they paid $11 billion for stage two drug that was unheard of at the time. now looking like it is a good acquisition. lex that i think has really simulated a lot of the current production. there is a lot of pushback. one of our reporters wrote a story about managed care rushing back on the actual pricing. >> pricing is a big issue. expensive,s really tens of thousands of dollars. these companies have pricing power. will they continue to have pricing power? >> i do not think you will ever see the government pushback where they have negotiating prices or in germany the same thing happening. the free-market is part of the society and constitution. that being said, the u.s. government has assumed a much greater role into health care they need to cut costs. year the number one ranked analyst in the group has said make it easy on a handful oft by these thi

play politics marine across the river explain the reasons behind the move to my colleague andrew pharma. they're saying that this is an alliance of the situation on for them in ukraine and of course crimea but this is a sad excuse really for puerto millions of lives at risk which is exactly what they're doing because drug trafficking is linked to terrorism as we know and it's essential for countries to come together to eliminate this threat this isn't a game here we know that for example in russia which is the main conduit of drugs originating from of ghana stand over ninety percent of addicts in this country use heroin the market is valued at six a billion u.s. dollars the market has value of one point five billion dollars and this is the bread and butter of people who are looking to hurt countries like the united states so it's not just russia that stands to lose here it's them as well as well as other countries around the world having said that i was surprised by the sort of relaxed stance that the u.s. has taken towards drug trafficking not really afghanistan really is a sore point

in the pharma business french you can't actually have over the counter drugs on law and in japan you know they have a local just a patient rate for women there are bunch of different structural reforms they could do none of these things are happening so you know the whole thing is about that's kind of increasing population to is not a problem you know they have a very big demographic problem and that's one of the reasons that they need growth because without growth it's going to be very difficult to be able to have as many benefits for the older population now we only have one minute left but i really want to get the senate how are our policies doing in stopping deflation altogether and isn't leading to any growth do you think i don't think it's going to lead to any growth i think that the growth is out i think if you're going to. one growth what you need is some sort of structural reform you need to have full employment on top of that because in order to get wage growth you need to first move to full employment that will give workers some degree of power with the learning mario to b

advisory board which is constituted by remarkable group of academics from small business and from big pharmanerated a substantial list that would will exceed the dollars that are proposed here. so we have a lot of exciting ideas about how to use that money. this is an opportunity in a very bold, innovative proactive way to try to tackle some of those obstacles that still make it far too slow and t too failure prone to develop drugs and devices, despite the remarkable advances in basic science. so we are pleased and excited to have that additional boost. >> any other questions? spent yes. i had a question for dr. collins. i was wondering about what was touted in the president's request as a sort of dark or light initiative. is this an increase to the high risk high reward, or is this a new program? is that entirely out of this opportunity growth and sustainability initiative or will it come out of other nih budget? >> let me explain. this is out of the budget which is within the ryan-murray envelope, $30 million to utilize within our common fund to tackle projects which would be particularly

large pharma has a great ap tied for life science companies with great ideas.like biotech and small cap. activity will trickle into technology. >> if this higher rate trend actually holds, i'm not sure it will, be careful -- did you see what happened to utilities to reits. reits were down over 2%. those interest rate sensitive groups immediately tanked. if they hold on to the higher rate concepts, it will affect them. >> somebody said to me the sell-off was nothing more than high frequency noise, this was an algorithm that was listening for certain words she might say. when they heard them it sold automatically. >> i think comments like that are, frankly, silly. there have been sell-offs long before there were high frequency trading. there was good reason for traders to listen to what yellen was saying. when she said six months, i popped up. they never give us those kind of moments. that was a tradeable moment. >> i was going to say that was a freudian slip on her part. there's no doubt about it. she might be happy the market is selling you have a little bit be

pharma, health care, insurance players also posting gains.at hertz also on the move on reports it is preparing to spin off its construction equipment rental business. twitter shares not participating in the rally following news that the ceo is planning a trip to china to meet with government officials. twitter has been blocked by chinese censors since 2009. stock down frictional ll ll lly fractionally in today's trade. >> earlier on, stephen wiseiss said he sold out of twitter at a loss. >> and we have someone who says stephen just made a mistake by selling. what made you sell. what was the big red flag for you on twitter? >> well, first of all, i have made mistakes before, so it's not unusual as a trader to make mistakes. so here is what it was. i bought twitter and i bought facebook at the same time, but i bought twitter because it was after the quarter. i thought it may have been oversold, and i'm very positive on the market, thought momentum would continue in the stock. now, the company missed the very objectives he set as their first qua